Market Size of Netherlands In-Vitro Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.28 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Netherlands In Vitro Diagnostics Market Analysis
The Netherlands in vitro diagnostics (IVD) market is expected to register a CAGR of 5.28% over the forecast period.
The COVID-19 pandemic significantly affected the invitro diagnostic market in the Netherlands owing to factors such as delayed laboratory appointments and reduced diagnostics. For instance, as per an article published in February 2022 by PubMed, the largest decrease in diagnostics was seen during the first lockdown, when the number of pathology reports declined up to 88%, and almost all specimen types were affected in the Netherlands. Pathologists were among them, receiving fewer specimens than usual, particularly during the lockdown. However, with restrictions lifted, the invitro diagnostics market is likely to witness growth in the coming years due to the rise in chronic disease, increase in testing laboratories, and demand for point-of-care testing.
The major factors fuelling this market include a rapid increase in chronic diseases, increasing demand for point-of-care testing and personalized medicine, and technological advances, along with the rising geriatric population in the country. For instance, according to VZinfo, in 2021, 53,100 new patients with diabetes were estimated to be diagnosed in the Netherlands. This estimated 29,600 men and 23,500 women (3.4 per 1,000 men and 2.7 per 1,000 women). In almost all age groups, the number is higher for men than for women. In addition, patients can deal with their conditions better with the help of IVDs (diabetic patients can use portable blood glucose monitors regularly to determine their blood glucose level). Furthermore, as per a Centraal Bureau Voor de Statistiek report in 2021, half of Dutch adults were overweight and 13.9% were severely overweight or obese and more prone to chronic diseases. The demand for IVD products is influenced by the increase in incidences of chronic diseases, thereby pushing market growth. Furthermore, government schemes to reduce the cost of IVD procedures in the Netherlands are also anticipated to promote market growth. For instance, according to the European Diagnostic Manufacturers Association (EDMA), the cost of IVDs is less than EUR 21 per person per year.
